From Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power Crunch
Issued on behalf of LIXTE Biotechnology Holdings, Inc. One of the most dramatic corporate reinventions of 2026 is taking a clinical-stage biotech and rebuilding it as a power-infrastructure company — aimed squarely at the electricity shortage throttling the AI boom. BOCA RATON, Fla., June...
Issued on behalf of LIXTE Biotechnology Holdings, Inc. One of the most dramatic corporate reinventions of 2026 is taking a clinical-stage biotech and rebuilding it as a power-infrastructure company — aimed squarely at the electricity shortage throttling the AI boom. BOCA RATON, Fla., June...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.